Novo Nordisk's next-gen obesity drug CagriSema trial results disappoint investors US$ 24.50 Min. order: 1 piece ★★★★★ 4.6 (282 reviews) Sold : Login>>
Novo Nordisk Offers New Contender in Weight Management US$ 26.12 Min. order: 1 piece ★★★★★ 4.4 (99 reviews) Sold : Login>>
Novo Nordisk's CagriSema Falls Short in Head-to-Head Trial vs Zepbound | Bryce Platt, PharmD posted on the topic US$ 28.71 Min. order: 1 piece ★★★★★ 4.2 (112 reviews) Sold : Login>>
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug US$ 28.21 Min. order: 1 piece ★★★★★ 4.5 (35 reviews) Sold : Login>>
Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment US$ 22.44 Min. order: 1 piece ★★★★★ 4.7 (295 reviews) Sold : Login>>